Linked from

The 74 pages that link to Dopamine, each with the reason it gives.

• Parkinson's diseaseRelated: Reduced dopamine signaling in motor circuits contributes to slowness and rigidity.

• NorepinephrineRelated: Dopamine is converted into norepinephrine in noradrenergic cells.

• Attention deficit hyperactivity disorderRelated: Dopamine pathways are among the targets of stimulant medications used for ADHD.

• CaffeineRelated: Adenosine A2A receptors interact with dopamine signaling in circuits affected by caffeine.

• Basal gangliaRelated: Dopamine changes how striatal neurons respond to cortical input and action outcomes.

• ProlactinRelated: Hypothalamic dopamine continuously suppresses prolactin secretion from pituitary lactotrophs.

• DelusionRelated: Dopamine dysregulation is linked to aberrant salience in psychosis.

• Reward systemRelated: Its signals help update behavior when outcomes differ from expectations.

• NicotineRelated: Nicotine indirectly increases dopamine signaling in reward circuits, reinforcing repeated use.

• DesireRelated: Dopamine signaling contributes to motivational pursuit without simply encoding pleasure.

• Romantic loveRelated: Reward-related dopamine systems contribute to the motivational pull of romantic attraction.

• AddictionRelated: Dopamine signaling helps the brain learn which cues predict drug effects and other rewards.

• Neuroleptic malignant syndromeRelated: Reduced dopamine signaling, especially in motor pathways, is central to the syndrome’s proposed mechanism.

• AmphetamineRelated: Amphetamine raises extracellular dopamine, contributing to its effects and misuse potential.

• Dopamine D2 receptorRelated: Dopamine is the endogenous ligand that activates D2 receptors.

• BupropionRelated: Reduced dopamine reuptake contributes to bupropion’s effects on mood and nicotine dependence.

• Tardive dyskinesiaRelated: Dopamine-blocking drugs can alter movement circuits and are the main medication-related risk.

• AnhedoniaRelated: Dopamine signaling is more closely tied to wanting and effort than to pleasure itself.

• LevodopaRelated: Levodopa raises brain dopamine by serving as its immediate biochemical precursor.

• ManiaRelated: Dopamine signaling is one proposed contributor to changes in reward and motivation during mania.

• Restless legs syndromeRelated: Dopaminergic signaling helps explain why dopamine-targeting medicines can relieve symptoms.

• BuspironeRelated: Buspirone’s active metabolite also interacts with dopamine D₂ receptors.

• Extrapyramidal symptomsRelated: Dopamine blockade in motor pathways is a common mechanism behind these medication-related movement disorders.

• AkathisiaRelated: Dopamine-blocking drugs commonly trigger akathisia, though its biology is not fully explained by dopamine alone.

• CatatoniaRelated: Dopamine signaling is implicated in catatonia and helps explain risks from dopamine-blocking drugs.

• Dopamine receptorRelated: It is the endogenous ligand that activates dopamine receptors.

• ByssusRelated: Dopamine-derived chemistry helps explain the wet adhesion of some mussel proteins.

• Impulse control disorderRelated: Dopamine-mediated learning can reinforce actions that produce immediate reward or relief.

• MDMARelated: MDMA also increases dopamine signaling, which contributes to stimulation and reinforcement.

• Nicotine dependenceRelated: Nicotine increases dopamine signaling that helps make nicotine use rewarding.

• Psychoactive drugRelated: Changes in dopamine signaling help explain reinforcement and the effects of several drug classes.

• DyskinesiaRelated: Fluctuating dopamine signaling helps shape the timing and severity of levodopa-related movements.

• StimulantRelated: Many stimulants increase dopamine signaling, contributing to alertness and reinforcement.

• AmantadineRelated: Amantadine can increase dopaminergic signaling, which helps explain its use in Parkinson’s disease.

• LibidoRelated: Dopamine-related motivation contributes to how rewarding and compelling sexual cues feel.

• ParkinsonismRelated: Reduced dopaminergic signaling contributes to bradykinesia and often responds to replacement therapy.

• Tourette syndromeRelated: Dopaminergic signaling is one target of treatments that reduce severe tics.

• VareniclineRelated: Varenicline alters nicotine-linked dopamine signaling in reward pathways.

• CatecholRelated: Dopamine is a familiar biological molecule built around catechol functionality.

• ChoreaRelated: Dopamine-modifying medicines can either reduce chorea or trigger it, depending on the condition and treatment.

• AtomoxetineRelated: In the prefrontal cortex, norepinephrine transporter blockade also reduces dopamine clearance.

• PleasureRelated: Dopamine contributes more to motivational pursuit and learning than to pleasure alone.

• ProlactinomaRelated: Reduced dopamine signaling can raise prolactin, while dopamine-mimicking drugs often shrink these tumors.

• SelegilineRelated: Slowing dopamine breakdown helps compensate for dopamine loss in Parkinson’s disease.

• CatalepsyRelated: Dopamine-blocking drugs can induce cataleptic states in experimental animals.

• Delusional parasitosisRelated: Dopamine-related mechanisms are proposed, but they do not fully explain the condition.

• PramipexoleRelated: Pramipexole mimics dopamine’s action when signaling is deficient.

• AgomelatineRelated: 5-HT2C blockade can increase dopamine release in frontal brain regions.

• CathinoneRelated: Changes in dopamine signaling contribute to cathinone’s reinforcing and activating effects.

• HyperactivityRelated: Dopamine systems are implicated in ADHD, but hyperactivity is not reducible to a single chemical cause.